Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

496 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genome-wide miRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers.
Heller G, Weinzierl M, Noll C, Babinsky V, Ziegler B, Altenberger C, Minichsdorfer C, Lang G, Döme B, End-Pfützenreuter A, Arns BM, Grin Y, Klepetko W, Zielinski CC, Zöchbauer-Müller S. Heller G, et al. Among authors: zielinski cc. Clin Cancer Res. 2012 Mar 15;18(6):1619-29. doi: 10.1158/1078-0432.CCR-11-2450. Epub 2012 Jan 26. Clin Cancer Res. 2012. PMID: 22282464
Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer.
Köstler WJ, Schwab B, Singer CF, Neumann R, Rücklinger E, Brodowicz T, Tomek S, Niedermayr M, Hejna M, Steger GG, Krainer M, Wiltschke C, Zielinski CC. Köstler WJ, et al. Among authors: zielinski cc. Clin Cancer Res. 2004 Mar 1;10(5):1618-24. doi: 10.1158/1078-0432.ccr-0385-3. Clin Cancer Res. 2004. PMID: 15014012
Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer.
Köstler WJ, Hudelist G, Rabitsch W, Czerwenka K, Müller R, Singer CF, Zielinski CC. Köstler WJ, et al. Among authors: zielinski cc. J Cancer Res Clin Oncol. 2006 Jan;132(1):9-18. doi: 10.1007/s00432-005-0038-8. Epub 2005 Sep 24. J Cancer Res Clin Oncol. 2006. PMID: 16184380
Perturbation of the tumor necrosis factor--related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5.
Horak P, Pils D, Kaider A, Pinter A, Elandt K, Sax C, Zielinski CC, Horvat R, Zeillinger R, Reinthaller A, Krainer M. Horak P, et al. Among authors: zielinski cc. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8585-91. doi: 10.1158/1078-0432.CCR-05-1276. Clin Cancer Res. 2005. PMID: 16361541
Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial.
Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N, Ciuleanu T, Cucevic B, Gyurkovits K, Ulsperger E, Jassem J, Grgic M, Saip P, Szilasi M, Wiltschke C, Wagnerova M, Oskina N, Soldatenkova V, Zielinski C, Wenczl M; Central European Cooperative Oncology Group CECOG. Brodowicz T, et al. Lung Cancer. 2006 May;52(2):155-63. doi: 10.1016/j.lungcan.2006.01.006. Epub 2006 Mar 29. Lung Cancer. 2006. PMID: 16569462 Clinical Trial.
496 results